Mefr mefr gine 29 mutts

Tha aillse sgamhain air a bhith na phrìomh adhbhar de bhàsan aillse air feadh an t-saoghail, a 'bagairt air slàinte daonna. Cunntasan aillse sgamhain cealla nach eil beag-chillte ann airson timcheall air 80% de dh 'euslaintich aillse sgamhain. Is e EGFR an-dràsta an targaid moilecular as cudromaiche airson a bhith a 'làimhseachadh aillse gun chealla nach beag. The phosphorylation of EGFR can promote tumor cell growth, differentiation, invasion, metastasis, anti-apoptosis, and promote tumor angiogenesis. EGFR tyrosine kinase inhibitors (TKI) can block the EGFR signaling pathway by inhibiting EGFR autophosphorylation, thereby inhibiting the proliferation and differentiation of tumor cells, promoting tumor cell apoptosis, reducing tumor angiogenesis, etc., so as to achieve tumor targeted therapy. A large number of studies have shown that the therapeutic efficacy of EGFR-TKI is closely related to the status of EGFR gene mutation, and can specifically inhibit the growth of tumor cells with EGFR gene mutation. Tha an EGFR Gene air a 'ghàirdean goirid de chromosome 7 (7p12), le làn fhaid de 200kb agus tha 28 Evons ann. The mutated region is mainly located in exons 18 to 21, codons 746 to 753 deletion mutation on exon 19 accounts for about 45% and the L858R mutation on exon 21 accounts for about 40% to 45%. The NCCN Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer clearly states that EGFR gene mutation testing is required before EGFR-TKI administration. This test kit is used to guide the administration of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) drugs, and provide the basis for personalized medicine for patients with non-small cell lung cancer. Chan eilear a 'cleachdadh a' phaid seo ach airson a bhith a 'lorg mhutanan cumanta anns na gine EGFR ann an euslaintich le aillse nach eil a' sgèith cealla. Tha toraidhean an deuchainn airson iomradh clionaigeach a-mhàin agus cha bu chòir a chleachdadh mar an aon bhunait airson làimhseachadh pearsanta air euslaintich. Clinicians should consider the patient's condition, drug indications, and treatment The reaction and other laboratory test indicators and other factors are used to comprehensively judge the test results.